IP Library Granted Patent US 9,540,650
Granted Patent B2
US 9,540,650 · App. 14/358,895 · Granted Jan 10, 2017

Nucleic acid fragment binding to target protein

Inventors: Ichiro Hirao (Tokyo, JP); Michiko Hirao (Tokyo, JP); Rie Yamashige (Saitama, JP); Shigeyuki Yokoyama (Saitama, JP)
Assignee: TAGCYX BIOTECHNOLOGIES
C12N15/115A61K48/00C12N15/1048C12N15/111C12N15/113C12Q1/6869G01N33/5308C12N2310/12C12N2310/16C12N2310/33C12N2310/331C12N2320/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,650
App. No.
14/358,895
Granted
Jan 10, 2017
Kind
B2
Abstract

An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a DNA aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base. The present invention also provides a method for sequencing a non-natural nucleotide-containing single-stranded nucleic acid molecule selected from a single-stranded nucleic acid library.

Claims (11)

1. A transcribable or replicable nucleic acid aptamer comprising:

natural nucleotides and

non-natural nucleotides having an artificial base-pairable artificial base,

wherein the artificial base is selected from the group consisting of 7-(2-thienyl)-3H-imidazo[4,5-b]pyridin-3-yl, 2-nitropyrrol-1-yl, and 2-formyl-1H-pyrrol-1-yl, and wherein the nucleic acid aptamer is directed against interferon γ as a target substance,

wherein the nucleic acid aptamer comprises any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 167 to 174 (provided that “n” in the sequences represents 7-(2-thienyl)-3H-imidazo[4,5-b]pyridin-3-yl), 186, 188, 190, 192, 194, 214 to 222, and 279 to 328.

2. The nucleic acid aptamer according to claim 1 , wherein the artificial base includes an artificial base-pairable derivative of the artificial base.

3. The nucleic acid aptamer according to claim 1 , wherein the content of the non-natural nucleotide is 20% or less of the total number of nucleotides.

4. The nucleic acid aptamer according to claim 1 , wherein the nucleic acid is a DNA or an RNA.

5. The nucleic acid aptamer according to claim 1 , wherein the nucleic acid aptamer consists of any one nucleotide sequence according to claim 1 that is 5′ flanked by the nucleotide sequence represented by SEQ ID NO: 1 and 3′ flanked by the nucleotide sequence represented by SEQ ID NO: 2.

6. A pharmaceutical composition which comprises a nucleic acid aptamer according to claim 1 as an active ingredient and functionally inhibits a target substance of the nucleic acid aptamer.

7. A pharmaceutical composition for functional inhibition of interferon γ, comprising a nucleic acid aptamer according to claim 1 as an active ingredient.

Assignments (3)
CHANGE OF ASSIGNEE ADDRESS Recorded Feb 28, 2018
From: TAGCYX BIOTECHNOLOGIES
To: TAGCYX BIOTECHNOLOGIES
Reel/Frame 045472/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2016
From: RIKEN
To: TAGCYX BIOTECHNOLOGIES
Reel/Frame 038026/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2014
From: HIRAO, ICHIRO; HIRAO, MICHIKO; YAMASHIGE, RIE; YOKOYAMA, SHIGEYUKI
To: RIKEN; TAGCYX BIOTECHNOLOGIES
Reel/Frame 034047/0489 →
Priority Claims (2)
JP 2011-253357 · Nov 18, 2011 · national
JP 2012-148962 · Jul 2, 2012 · national
Continuity (1)
Related Publication 20150119254A1 · Apr 30, 2015